The epidermal growth factor receptor is frequently overexpressed in penile squamous cell carcinomas

A tissue microarray and digital image analysis study of 112 cases

Alcides Chaux, Enrico Munari, Betina Katz, Rajni Sharma, Kristen Lecksell, Antonio L. Cubilla, Arthur Burnett, George J. Netto

Research output: Contribution to journalArticle

Abstract

Disseminated penile cancer is usually treated with chemotherapy. However, response rates are far from acceptable. Recently, anti-epidermal growth factor receptor (EGFR) monoclonal antibodies have shown to be clinically useful in penile carcinomas. Nevertheless, only a few cases of penile carcinomas have been evaluated for EGFR expression. In this study, we assessed the immunohistochemical expression of EGFR in 112 patients with penile squamous cell carcinoma. We built 4 tissue microarrays and evaluated EGFR expression using a monoclonal mouse anti-EGFR antibody. For digital image analysis, we used the open-source software ImageJ version 1.47 (NIH, Bethesda, MD) along with the immunomembrane plug-in. Membranous EGFR expression was evaluated, taking into account staining completeness (0-10 points) and staining intensity (0-10 points) for a combined score (0-20 points). We classified the cases as follows: negative EGFR expression, 0 to 3 points; low EGFR expression, 4 to 8 points; and high EGFR expression, 9 to 20 points. The distribution of EGFR immunohistochemical expression was as follows: 13 cases (12%) were EGFR negative, 49 cases (44%) had low EGFR expression, and 50 cases (44%) had high EGFR expression. EGFR expression was not associated with histologic subtype (P =.47), histologic grade (P =.77), or human papillomavirus status (P =.14). In conclusion, immunohistochemical EGFR expression appears to be a common feature of penile carcinomas, independently of histologic subtype, histologic grade, and human papillomavirus presence. Whether or not EGFR expression is associated with EGFR gene mutation or if it can be used to predict response to therapy in patients with disseminated penile cancer should be evaluated in future studies.

Original languageEnglish (US)
Pages (from-to)2690-2695
Number of pages6
JournalHuman Pathology
Volume44
Issue number12
DOIs
StatePublished - Dec 2013

Fingerprint

Epidermal Growth Factor Receptor
Squamous Cell Carcinoma
Penile Neoplasms
Carcinoma
Staining and Labeling
erbB-1 Genes
Software

Keywords

  • Digital image analysis
  • Epidermal growth factor receptor
  • Penile cancer
  • Squamous cell carcinomas
  • Targeted therapy

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

The epidermal growth factor receptor is frequently overexpressed in penile squamous cell carcinomas : A tissue microarray and digital image analysis study of 112 cases. / Chaux, Alcides; Munari, Enrico; Katz, Betina; Sharma, Rajni; Lecksell, Kristen; Cubilla, Antonio L.; Burnett, Arthur; Netto, George J.

In: Human Pathology, Vol. 44, No. 12, 12.2013, p. 2690-2695.

Research output: Contribution to journalArticle

Chaux, Alcides ; Munari, Enrico ; Katz, Betina ; Sharma, Rajni ; Lecksell, Kristen ; Cubilla, Antonio L. ; Burnett, Arthur ; Netto, George J. / The epidermal growth factor receptor is frequently overexpressed in penile squamous cell carcinomas : A tissue microarray and digital image analysis study of 112 cases. In: Human Pathology. 2013 ; Vol. 44, No. 12. pp. 2690-2695.
@article{f9837510bba74050b72aa8c56574e70d,
title = "The epidermal growth factor receptor is frequently overexpressed in penile squamous cell carcinomas: A tissue microarray and digital image analysis study of 112 cases",
abstract = "Disseminated penile cancer is usually treated with chemotherapy. However, response rates are far from acceptable. Recently, anti-epidermal growth factor receptor (EGFR) monoclonal antibodies have shown to be clinically useful in penile carcinomas. Nevertheless, only a few cases of penile carcinomas have been evaluated for EGFR expression. In this study, we assessed the immunohistochemical expression of EGFR in 112 patients with penile squamous cell carcinoma. We built 4 tissue microarrays and evaluated EGFR expression using a monoclonal mouse anti-EGFR antibody. For digital image analysis, we used the open-source software ImageJ version 1.47 (NIH, Bethesda, MD) along with the immunomembrane plug-in. Membranous EGFR expression was evaluated, taking into account staining completeness (0-10 points) and staining intensity (0-10 points) for a combined score (0-20 points). We classified the cases as follows: negative EGFR expression, 0 to 3 points; low EGFR expression, 4 to 8 points; and high EGFR expression, 9 to 20 points. The distribution of EGFR immunohistochemical expression was as follows: 13 cases (12{\%}) were EGFR negative, 49 cases (44{\%}) had low EGFR expression, and 50 cases (44{\%}) had high EGFR expression. EGFR expression was not associated with histologic subtype (P =.47), histologic grade (P =.77), or human papillomavirus status (P =.14). In conclusion, immunohistochemical EGFR expression appears to be a common feature of penile carcinomas, independently of histologic subtype, histologic grade, and human papillomavirus presence. Whether or not EGFR expression is associated with EGFR gene mutation or if it can be used to predict response to therapy in patients with disseminated penile cancer should be evaluated in future studies.",
keywords = "Digital image analysis, Epidermal growth factor receptor, Penile cancer, Squamous cell carcinomas, Targeted therapy",
author = "Alcides Chaux and Enrico Munari and Betina Katz and Rajni Sharma and Kristen Lecksell and Cubilla, {Antonio L.} and Arthur Burnett and Netto, {George J.}",
year = "2013",
month = "12",
doi = "10.1016/j.humpath.2013.07.012",
language = "English (US)",
volume = "44",
pages = "2690--2695",
journal = "Human Pathology",
issn = "0046-8177",
publisher = "W.B. Saunders Ltd",
number = "12",

}

TY - JOUR

T1 - The epidermal growth factor receptor is frequently overexpressed in penile squamous cell carcinomas

T2 - A tissue microarray and digital image analysis study of 112 cases

AU - Chaux, Alcides

AU - Munari, Enrico

AU - Katz, Betina

AU - Sharma, Rajni

AU - Lecksell, Kristen

AU - Cubilla, Antonio L.

AU - Burnett, Arthur

AU - Netto, George J.

PY - 2013/12

Y1 - 2013/12

N2 - Disseminated penile cancer is usually treated with chemotherapy. However, response rates are far from acceptable. Recently, anti-epidermal growth factor receptor (EGFR) monoclonal antibodies have shown to be clinically useful in penile carcinomas. Nevertheless, only a few cases of penile carcinomas have been evaluated for EGFR expression. In this study, we assessed the immunohistochemical expression of EGFR in 112 patients with penile squamous cell carcinoma. We built 4 tissue microarrays and evaluated EGFR expression using a monoclonal mouse anti-EGFR antibody. For digital image analysis, we used the open-source software ImageJ version 1.47 (NIH, Bethesda, MD) along with the immunomembrane plug-in. Membranous EGFR expression was evaluated, taking into account staining completeness (0-10 points) and staining intensity (0-10 points) for a combined score (0-20 points). We classified the cases as follows: negative EGFR expression, 0 to 3 points; low EGFR expression, 4 to 8 points; and high EGFR expression, 9 to 20 points. The distribution of EGFR immunohistochemical expression was as follows: 13 cases (12%) were EGFR negative, 49 cases (44%) had low EGFR expression, and 50 cases (44%) had high EGFR expression. EGFR expression was not associated with histologic subtype (P =.47), histologic grade (P =.77), or human papillomavirus status (P =.14). In conclusion, immunohistochemical EGFR expression appears to be a common feature of penile carcinomas, independently of histologic subtype, histologic grade, and human papillomavirus presence. Whether or not EGFR expression is associated with EGFR gene mutation or if it can be used to predict response to therapy in patients with disseminated penile cancer should be evaluated in future studies.

AB - Disseminated penile cancer is usually treated with chemotherapy. However, response rates are far from acceptable. Recently, anti-epidermal growth factor receptor (EGFR) monoclonal antibodies have shown to be clinically useful in penile carcinomas. Nevertheless, only a few cases of penile carcinomas have been evaluated for EGFR expression. In this study, we assessed the immunohistochemical expression of EGFR in 112 patients with penile squamous cell carcinoma. We built 4 tissue microarrays and evaluated EGFR expression using a monoclonal mouse anti-EGFR antibody. For digital image analysis, we used the open-source software ImageJ version 1.47 (NIH, Bethesda, MD) along with the immunomembrane plug-in. Membranous EGFR expression was evaluated, taking into account staining completeness (0-10 points) and staining intensity (0-10 points) for a combined score (0-20 points). We classified the cases as follows: negative EGFR expression, 0 to 3 points; low EGFR expression, 4 to 8 points; and high EGFR expression, 9 to 20 points. The distribution of EGFR immunohistochemical expression was as follows: 13 cases (12%) were EGFR negative, 49 cases (44%) had low EGFR expression, and 50 cases (44%) had high EGFR expression. EGFR expression was not associated with histologic subtype (P =.47), histologic grade (P =.77), or human papillomavirus status (P =.14). In conclusion, immunohistochemical EGFR expression appears to be a common feature of penile carcinomas, independently of histologic subtype, histologic grade, and human papillomavirus presence. Whether or not EGFR expression is associated with EGFR gene mutation or if it can be used to predict response to therapy in patients with disseminated penile cancer should be evaluated in future studies.

KW - Digital image analysis

KW - Epidermal growth factor receptor

KW - Penile cancer

KW - Squamous cell carcinomas

KW - Targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=84888024644&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84888024644&partnerID=8YFLogxK

U2 - 10.1016/j.humpath.2013.07.012

DO - 10.1016/j.humpath.2013.07.012

M3 - Article

VL - 44

SP - 2690

EP - 2695

JO - Human Pathology

JF - Human Pathology

SN - 0046-8177

IS - 12

ER -